Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03417284 | Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT00135200 | Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma | completed | Phase 2 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 30, 2025 |
| NCT02224729 | Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT03277105 | A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 522 | Janssen Research & Development, LLCINDUSTRY | 18 | Apr 29, 2025 | clinicaltrials |
| NCT03412565 | A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | completed | Phase 2 | 265 | Janssen Research & Development, LLCINDUSTRY | 9 | Apr 29, 2025 | clinicaltrials |
| NCT04100044 | Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma | completed | N/A | 9 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT01998971 | A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | completed | Phase 1 | 240 | Janssen Research & Development, LLCINDUSTRY | 3 | Apr 25, 2025 | clinicaltrials |
| NCT03939182 | Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma | completed | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05347485 | A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma | completed | Phase 2 | 86 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05673967 | Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma | completed | — | 62 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT02566304 | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 35 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT03860038 | TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 113 | TJ Biopharma Co., Ltd.INDUSTRY | 2 | Apr 24, 2025 | clinicaltrials |
| NCT04578600 | CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | completed | Phase 1 | 8 | Joseph TuscanoOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05690230 | Improving Patient Experience: BMBA | completed | N/A | 60 | Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04566978 | 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) | completed | Early Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT05555329 | Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study(POMAlternative) | completed | Phase 4 | 12 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT01303887 | A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients(PACIFICO) | completed | Phase 3 | 680 | University of LiverpoolOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT00511082 | Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | completed | Phase 1 | 7 | Otsuka Beijing Research InstituteINDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT03288974 | Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea(Pomalyst PMS) | completed | — | 397 | CelgeneINDUSTRY | 1 | Apr 15, 2025 | clinicaltrials |
| NCT02541383 | A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma(Cassiopeia) | completed | Phase 3 | 1,085 | Intergroupe Francophone du MyelomeNETWORK | 3 | Apr 13, 2025 | clinicaltrials |
| NCT03311958 | Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance | completed | Early Phase 1 | 15 | Fox Chase Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04849351 | Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma | completed | Phase 2 | 178 | Hutchison Medipharma LimitedINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04758767 | CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 10 | CASI pharmaceuticals, Inc.INDUSTRY | 2 | Apr 3, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT03700450 | Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma | completed | Phase 2 | 37 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT03734016 | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia(ALPINE) | completed | Phase 3 | 652 | BeiGeneINDUSTRY | 15 | Mar 30, 2025 | clinicaltrials |
| NCT02555839 | Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice | completed | — | 127 | CelgeneINDUSTRY | 1 | Mar 28, 2025 | clinicaltrials |
| NCT03442673 | Chemotherapy and G-CSF for Mobilization(MOCCCA) | completed | Phase 2 | 137 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT05108805 | Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting | completed | Phase 4 | 25 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT06892119 | Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation | completed | Phase 1 | 6 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT01163357 | Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | completed | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT00120263 | Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma | completed | N/A | 92 | London Health Sciences CentreOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT03748953 | Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) | completed | Phase 3 | 37 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT01758328 | Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04939844 | REST - Replacing Steroids in the Transplant Ineligble(REST) | completed | Phase 2 | 51 | Oslo University HospitalOTHER | 2 | Mar 20, 2025 | clinicaltrials |
| NCT05227144 | Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 31 | ORIC PharmaceuticalsINDUSTRY | 2 | Mar 20, 2025 | clinicaltrials |
| NCT02506959 | Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma | completed | Phase 2 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT03269136 | PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma | completed | Phase 1 | 101 | PfizerINDUSTRY | 2 | Mar 18, 2025 | clinicaltrials |
| NCT01186224 | Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)(PHANTASTIC) | completed | N/A | 60 | University of LiverpoolOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04178798 | Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 22 | PETHEMA FoundationOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06610045 | The Burden of Multiple Myeloma on Patients and Caregivers Quality of Life: a Canadian Real-World Study | completed | — | 400 | PeriPharmOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT02924272 | Ixazomib Rollover Study | completed | Phase 2 | 32 | TakedaINDUSTRY | 11 | Mar 12, 2025 | clinicaltrials |
| NCT00719888 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | completed | Phase 2 | 135 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT01865110 | R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL | completed | Phase 3 | 623 | The Lymphoma Academic Research OrganisationOTHER | 7 | Mar 5, 2025 | clinicaltrials |
| NCT04304144 | A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis | completed | Phase 2 | 25 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 1, 2025source: clinicaltrials